Head and Neck Cancer Market
The global head and neck cancer market is driven by increase in the patient population, rise in health care infrastructure in developing economies, growth of the pharmaceutical industry, surge in research and development activity, increase in product approvals, and rise in government initiatives. An estimated 75% of head and neck cancers is caused due to consumption of alcohol and tobacco. However, high cost of treatment and high failure rate of late stage clinical trials are the major factors restraining the global market.
The global head and neck cancer market has been segmented based on drug class, distribution channel, and region. In terms of drug class, the global market has been classified into EFGR inhibitors, mitotic inhibitors, anti-PD-1 monoclonal antibodies, and others. The anti-PD-1 monoclonal antibodies segment is projected to account for major share of the market by the end of the forecast period. Increase in research and development activity in the pharmaceutical industry, development of new products, and rise in mergers & acquisitions are expected to drive the segment during the forecast period. Based on distribution channel, the global head and neck cancer market has been classified into hospital pharmacies, retail pharmacies, and e-commerce. In terms of region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Based on drug class, the anti-PD-1 monoclonal antibodies segment is anticipated to dominate the global head and neck cancer market. Increase in awareness, rise in demand for efficient drugs for treatment, and new product approvals are expected to propel the segment during the forecast period. For instance, in November 2016, Bristol-Myers Squibb received the FDA approval for Opdivo (nivolumab) for intravenous treatment of individuals with metastatic squamous cell carcinoma of the head and neck (SCCHN)
In terms of distribution channel, the hospital pharmacies segment dominated the global head and neck cancer market. Increase in patient population and improvement in health care infrastructure are expected to drive the segment during the forecast period.
North America accounted for the largest share of the global market in 2017. Rise in prevalence of head and neck cancer (HNC), surge in health care expenditure, growth of the pharmaceutical industry, rise in mergers & acquisitions, and robust product pipeline are anticipated to drive the market in the region during the forecast period. Rise in demand for efficient drugs for treatment of HNCs in emerging economies such as China and India, growing pharmaceutical industry, and rapidly increasing patient population are anticipated to fuel the growth of the market in Asia Pacific during the forecast period. The head and neck cancer market in Latin America and Middle East & Africa is expected to be driven by rise in government initiatives to promote better health care facilities and increase in investment in health care sector during the forecast period. Growth of the health care industry, increase in the number of pharmaceutical companies, and rise in demand for therapeutics are expected to augment the market in these regions during the forecast period.
Major players operating in the global head and neck cancer market include Sanofi, Pfizer, Eli Lilly and Company, Merck KgaA, Bristol-Myers Squibb Company, Bayer AG, Galera, Fresenius Kabi, and Teva Pharmaceuticals. Increase in mergers & acquisitions, new product development, and strategic collaboration between major companies and governing authorities are expected to drive the global market during the forecast period. In October 2018, Sanofi received the FDA approval for TAXOTERE for the treatment of patients with head and neck cancer.
The global head and neck cancer market has been segmented as below:
|
Drug Class |
|
|
Distribution Channel |
|
|
Region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Head and Neck Cancer (HNC) Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Head and Neck Cancer (HNC) Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
6. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2016–2026
6.3.1. EGFR Inhibitors
6.3.2. Mitotic Inhibitors
6.3.3. Anti-PD-1 Monoclonal Antibodies
6.3.4. Others
6.4. Market Attractiveness by Drug Class
7. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2016–2026
7.3.1. Hospitals Pharmacies
7.3.2. Retail Pharmacies
7.3.3. E-commerce
7.4. Market Attractiveness, by Distribution Channel
8. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Head and Neck Cancer (HNC) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2016–2026
9.2.1. EGFR Inhibitors
9.2.2. Mitotic Inhibitors
9.2.3. Anti-PD-1 Monoclonal Antibodies
9.2.4. Others
9.3. Market Value Forecast, by Distribution Channel, 2016–2026
9.3.1. Hospitals Pharmacies
9.3.2. Retail Pharmacies
9.3.3. E-commerce
9.4. Market Value Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Head and Neck Cancer (HNC) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2016–2026
10.2.1. EGFR Inhibitors
10.2.2. Mitotic Inhibitors
10.2.3. Anti-PD-1 Monoclonal Antibodies
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2016–2026
10.3.1. Hospitals Pharmacies
10.3.2. Retail Pharmacies
10.3.3. E-commerce
10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Head and Neck Cancer (HNC) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2016–2026
11.2.1. EGFR Inhibitors
11.2.2. Mitotic Inhibitors
11.2.3. Anti-PD-1 Monoclonal Antibodies
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2016–2026
11.3.1. Hospitals Pharmacies
11.3.2. Retail Pharmacies
11.3.3. E-commerce
11.4. Market Value Forecast, by Country/Sub-region, 2016–2026
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of APAC
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Head and Neck Cancer (HNC) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2016–2026
12.2.1. EGFR Inhibitors
12.2.2. Mitotic Inhibitors
12.2.3. Anti-PD-1 Monoclonal Antibodies
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2016–2026
12.3.1. Hospitals Pharmacies
12.3.2. Retail Pharmacies
12.3.3. E-commerce
12.4. Market Value Forecast, by Country/Sub-region, 2016–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of LATAM
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Head and Neck Cancer (HNC) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2016–2026
13.2.1. EGFR Inhibitors
13.2.2. Mitotic Inhibitors
13.2.3. Anti-PD-1 Monoclonal Antibodies
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2016–2026
13.3.1. Hospitals Pharmacies
13.3.2. Retail Pharmacies
13.3.3. E-commerce
13.4. Market Value Forecast, by Country/Sub-region, 2016–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2017)
14.3. Company Profiles
14.3.1. Sanofi
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Eli Lilly and Company
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. AstraZeneca
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Teva Pharmaceuticals
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. F. Hoffmann-La Roche Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Fresenius Kabi
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Merck
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Bayer AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Bristol-Myers Squibb Company
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Galera
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
List of Tables
Table 01: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 03: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 04: North America Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country, 2016–2026
Table 05: North America Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 06: North America Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel,
Table 07: Europe Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08: Europe Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 09: Europe Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 11: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 12: Asia Pacific Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 14: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Middle East & Africa Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Middle East & Africa Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 18: Middle East & Africa Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
List of Figures
Figure 01: Global Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class (2017)
Figure 03: Global Head and Neck Cancer (HNC) Market Value Share (%), by Distribution Channel (2017)
Figure 04: Global Head and Neck Cancer (HNC) Market Value Share (%), by Region (2017)
Figure 05: Global Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 06: Global Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 07: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EGFR Inhibitors, 2016–2026
Figure 08: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Mitotic Inhibitors, 2016–2026
Figure 09: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-PD-1 Monoclonal Antibodies, 2016–2026
Figure 10: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others,
Figure 11: Global Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 12: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by
Figure 13: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 14: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2016–2026
Figure 15: Global Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 16: Global Head and Neck Cancer (HNC) Market Value Share Analysis, by Region, 2018 and 2026
Figure 17: Global Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Region, 2018–2026
Figure 18: North America Head and Neck Cancer (HNC) Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 19: North America Head and Neck Cancer (HNC) Market Value Share Analysis, by Country, 2018 and 2026
Figure 20: North America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country, 2018–2026
Figure 21: North America Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 22: North America Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 23: North America Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 24: North America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
Figure 25: Europe Head and Neck Cancer (HNC) Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: Europe Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 27: Europe Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 28: Europe Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 29: Europe Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 30: Europe Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 31: Europe Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
Figure 32: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 33: Asia Pacific Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 34: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 35: Asia Pacific Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 36: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 37: Asia Pacific Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 38: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
Figure 39: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 40: Latin America Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 41: Latin America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 42: Latin America Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 43: Latin America Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 44: Latin America Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 45: Latin America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
Figure 46: Middle East & Africa Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, 2016–2026
Figure 47: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 48: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 49: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 50: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 51: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 52: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 53: Global Head and Neck Cancer (HNC) Market Share, by Company, 2017
Figure 54: AstraZeneca Oncology Business Revenue (US$ Bn) & Y-o-Y Growth (%), 2014 –2017
Figure 55: AstraZeneca R&D in Oncology Segment Revenue (US$ Bn) & Y-o-Y Growth (%), 2014 –2017
Figure 56: AstraZeneca's Oncology Business Segment Revenue (% Share), by Region, 2017
Figure 57: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 58: Eli Lilly and Company Breakdown of Net Sales, by Region, 2017
Figure 59: Eli Lilly and Company Breakdown of Net Sales, by Business Segment, 2017
Figure 60: Eli Lilly and Company Research and Development Cost, 2016 and 2017 (US$ Mn)
Figure 61: Pfizer, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 62: Pfizer, Inc.’s Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 64: Pfizer, Inc.’s Revenue (% Share), by Business Segment, 2017
Figure 64: Pfizer, Inc.’s Revenue (% Share), by Business Segment, 2017
Figure 66: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 67: Novartis AG Oncology Business Segment Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure 68: Novartis AG’s Net Sales (% Share), by Business Segment, 2017
Figure 69: Novartis AG’s Net Sales (% Share), by Region, 2017
Figure 70: Bristol-Myers Squibb Company Revenue (US$ Bn), 2014-2017
Figure 71: Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
Figure 72: Bristol-Myers Squibb Company Revenue, by Geography, 2017
Figure 73: Bayer AG Pharmaceutical Business Segment Revenue (US$ Bn), 2015-2017
Figure 74: Bayer AG Pharmaceutical Business Segment R&D Expenditure (US$ Bn), 2015-2017
Figure 75: Bayer AG Pharmaceutical Business Segment Revenue, by Geography (2017)
Figure 76: F. Hoffmann-La Roche Ltd. Oncology Segment Revenue (US$ Bn), 2015–2017
Figure 77: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
Figure 78: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue, by Specialty (2017)
Figure 79: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue, by Region (2017)
Figure 80: Sanofi Revenue (US$ Bn), 2014-2017
Figure 81: Sanofi Regional Sales Breakdown (%), 2017
Figure 82: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 83: Teva Pharmaceutical Industries Ltd. Segmental Revenue (US$ Bn), 2017
Figure 84: Fresenius SE & Co. KGaA Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 85: Fresenius SE & Co. KGaA Breakdown of Net Sales (%), by Business Segment, 2017
Figure 86: Merck KGaA Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 87: Merck KGaA Revenue, by Geography (%), 2017
Figure 88: Merck KGaA Revenue, by Business Segment (%), 2014–2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes